Prelude Therapeutics: $3.45 Biotech Stock Pushing Oral Cancer Drugs Toward Clinical SuccessExplore how Prelude Therapeutics’ oral‑bioavailable small‑molecule cancer drugs could reshape oncology and its market prospects.PRELUDE THERAPEUTICS INC Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 16/11/2026, 13:22 2 minutes to read